Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) on April 7, 2026 launched a new NARCAN® Nasal Spray Carrying Case, expanded 6-count and 24-count multipacks, and began a college outreach effort titled Ready to Rescue featuring Emmitt Smith and Zac Clark.
The initiatives aim to increase naloxone access, address low carry rates, and support campus preparedness; carrying case is available on Amazon and multipacks on NarcanDirect.com.
AI-generated analysis. Not financial advice.
Positive
- New carrying case launched to improve daily naloxone portability
- 6-count and 24-count multipacks introduced for higher-volume distributors
- Campus outreach with spokespeople Emmitt Smith and Zac Clark to boost awareness
- Availability: carrying case on Amazon and multipacks on NarcanDirect.com
Negative
- None.
News Market Reaction – EBS
On the day this news was published, EBS declined 3.09%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EBS was down 1.58% while peers showed mixed moves: EOLS up 4%, CGC up 0.99%, KMDA up 0.36%, and SIGA down 0.95%, pointing to stock-specific trading rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Conference participation | Positive | -1.8% | Participation in four international preparedness conferences on health security threats. |
| Mar 25 | Government contracts | Positive | -1.6% | Over $60M in U.S. and international smallpox medical countermeasure awards. |
| Mar 03 | Board appointment | Positive | -0.8% | Appointment of experienced healthcare and financial executive to board and committees. |
| Feb 26 | Earnings results | Positive | -26.6% | FY 2025 turnaround with $742.9M revenue and return to net income and EBITDA strength. |
| Feb 26 | Buyback program | Positive | -26.6% | New $50M stock repurchase authorization replacing prior buyback program. |
Recent history shows EBS shares often declined on generally constructive news, including contracts, buybacks, and earnings, indicating a pattern of negative price reactions even to positive catalysts.
Over the last several months, EBS highlighted multiple milestones. On Feb 26, 2026, it reported Q4 and FY 2025 results with $742.9M full-year revenue, improved net income of $52.6M, and adjusted EBITDA of $205.0M, plus a new $50M buyback authorization and prior $24.8M repurchases. The company secured over $60M in smallpox countermeasure contracts and participated in major preparedness conferences. Despite these developments, each of the last five news events saw negative 24-hour price reactions, framing today’s NARCAN® access expansion within a backdrop of cautious trading.
Market Pulse Summary
This announcement highlights new NARCAN® Nasal Spray carrying cases, expanded 6- and 24-count multipacks, and college outreach aimed at improving opioid overdose preparedness, including among high-risk young adults. It builds on Emergent’s broader naloxone strategy by targeting distribution partners and campus communities. Investors may focus on how these offerings influence NARCAN® adoption, order volumes from public-interest customers, and longer-term franchise durability alongside existing government contracts and turnaround efforts noted in recent filings.
Key Terms
naloxone medical
stock repurchase program financial
adjusted ebidta financial
rule 10b5-1(c) regulatory
schedule 13g/a regulatory
AI-generated analysis. Not financial advice.
New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency
GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a series of initiatives designed to help increase access to NARCAN® Nasal Spray and encourage the public to be ready to respond to an opioid overdose. These include the launch of the new NARCAN® Nasal Spray Carrying Case, the expanded availability of NARCAN® Nasal Spray multipacks and a college campus engagement featuring Pro Football Hall of Famer, Emmitt Smith and Release Recovery Founder/CEO, Zac Clark at Southern Methodist University (SMU).
The new NARCAN® Nasal Spray Carrying Case is designed to be easy to carry, compact, discreet and durable, helping to ensure it's on hand when needed most. Additionally, Emergent is expanding the availability of NARCAN® Nasal Spray multipacks to include 6-count and 24-count options, specifically designed to meet the needs of partners distributing higher volumes of naloxone.
"The opioid epidemic continues to impact individuals and communities every day, and each tool we can provide to increase preparedness and reduce stigma is vital," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. "The availability of the NARCAN® Nasal Spray Carrying Case and multipack options underscores our commitment to making naloxone as accessible as possible. Coupled with our campus outreach, we are working to empower more people to respond in an opioid emergency."
In line with these expanded access efforts, Emergent's Ready to Rescue campaign will visit SMU with campaign spokespeople Emmitt Smith and Zac Clark to host a conversation with students focused on mental health, dismantling the stigma associated with accidental opioid overdose and the importance of carrying NARCAN® Nasal Spray.
Research indicates a significant need for increased preparedness, with a recent survey finding that only one in 10 of the general population currently carries naloxone.1 Among college students, a high-risk group, 81 percent expressed a preference for a case to carry NARCAN® Nasal Spray.2 The new carrying case, designed to clip easily onto backpacks or bags, addresses this need, making it a seamless part of daily life.
"The reality is that opioid overdose emergencies can happen anytime, anywhere and to anyone," said Emmitt Smith. "That's why I’m passionate about encouraging everyone – especially college students – to be prepared. Being ready to rescue means carrying NARCAN® Nasal Spray and knowing how to use it, because you never know when you could help save someone’s life."
Opioid misuse and dependency are highest among young adults ages 18 to 25,3 and about one in three college students know someone who has overdosed.4 With young adults having an increased risk of witnessing or experiencing an opioid emergency, building preparedness on college campuses has never been more important. To this end, Emergent is engaging with hundreds of college/university leaders across the country to increase awareness of the new carrying case and encourage life-saving efforts on their campuses.
"Every minute counts in an opioid emergency and having NARCAN® Nasal Spray readily available can be the difference between life and death," said Dr. Bonnie Milas, Clinical Professor of Anesthesiology and Critical Care Medicine at the University of Pennsylvania. "The new carrying case makes it simple to keep this life-saving medication with you, just like you would a first-aid kit, and with the multipacks, business and community organizations can ensure they have enough doses to be prepared."
The NARCAN® Nasal Spray Carrying Case is now available on Amazon. The NARCAN® Nasal Spray Multipacks are available on NarcanDirect.com for public interest customers. For more information, visit NARCAN.com.
Emmitt Smith and Zac Clark are paid spokespeople for Emergent BioSolutions.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
1 https://doi.org/10.1001/jamanetworkopen.2024.62698
2 Emergent BioSolutions. Consumer Research for NARCAN® Nasal Spray Carrying Case (509 adults online in Q3 2025). Data on file.
3 https://doi.org/10.3390/ijerph19010022
4 https://www.ue.org/risk-management/health-and-well-being/respond-to-student-opioid-overdoses
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3fcbfc65-93d7-475f-9f23-b47fbf2ab8ca
https://www.globenewswire.com/NewsRoom/AttachmentNg/2c07f51b-ca7f-456d-b090-34479583785e
https://www.globenewswire.com/NewsRoom/AttachmentNg/5162a7ae-5927-4115-a849-83c1dad70ffd
